Probiotic MR-61: a gut feeling against myopia?
NCT ID NCT07298824
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a probiotic called MR-61 can help slow the worsening of nearsightedness (myopia) in children and teens aged 3 to 18. Participants will take either the probiotic or a placebo daily for a period, and researchers will measure changes in their vision and eye length. The goal is to see if this simple supplement can reduce the need for stronger glasses over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 164 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Myopia is defined as spherical equivalent (SE) ≤ -0.5D. 2. Aged between 3 and 18 years, with no restriction on gender. 3. Cylinder power ≤ 1.50D; anisometropia of SE between both eyes ≤ 1.50D. 4. The subject has sufficient compliance with the study follow-up; the subject or their guardian has the intention to receive treatment and has signed the informed consent form. Exclusion Criteria: 1. Presence of other concomitant ocular diseases; 2. Abnormal findings on clinical slit-lamp examination; 3. Existence of amblyopia, manifest strabismus, esotropia, or other congenital ocular diseases; 4. Individuals with abnormal intraocular pressure or abnormal axial length of the eye; 5. Either or both parents having a spherical equivalent (SE) ≤ -6.00D; 6. Other conditions inconsistent with this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Myopia progressing are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Yifeng Yu
RECRUITINGNanchang, Jiangxi, 330008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.